| Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP JL Silverman, SS Tolu, CL Barkan, JN Crawley Neuropsychopharmacology 35 (4), 976-989, 2010 | 446 | 2010 |
| Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism JL Silverman, DG Smith, SJS Rizzo, MN Karras, SM Turner, SS Tolu, ... Science translational medicine 4 (131), 131ra51-131ra51, 2012 | 257 | 2012 |
| Sociability and motor functions in Shank1 mutant mice JL Silverman, SM Turner, CL Barkan, SS Tolu, R Saxena, AY Hung, ... Brain research 1380, 120-137, 2011 | 234 | 2011 |
| Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data M Kushnir, Y Choi, R Eisenberg, D Rao, S Tolu, J Gao, W Mowrey, ... The Lancet Haematology 6 (7), e359-e365, 2019 | 127 | 2019 |
| Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia A Emadi, R Faramand, B Carter‐Cooper, S Tolu, LA Ford, RG Lapidus, ... American journal of hematology 90 (5), E77-E79, 2015 | 111 | 2015 |
| Characterization of hematopoiesis in sickle cell disease by prospective isolation of stem and progenitor cells SS Tolu, K Wang, Z Yan, S Zhang, K Roberts, AS Crouch, G Sebastian, ... Cells 9 (10), 2159, 2020 | 19 | 2020 |
| Ultra-high-frequency reprogramming of individual long-term hematopoietic stem cells yields low somatic variant induced pluripotent stem cells K Wang, AK Guzman, Z Yan, S Zhang, MY Hu, MB Hamaneh, YK Yu, ... Cell reports 26 (10), 2580-2592. e7, 2019 | 18 | 2019 |
| Incidence of invasive fungal infections in patients initiating ibrutinib and other small molecule kinase inhibitors—United States, July 2016–June 2019 JAW Gold, SS Tolu, T Chiller, K Benedict, BR Jackson Clinical Infectious Diseases 75 (2), 334-337, 2022 | 10 | 2022 |
| Agranulocytosis from outpatient antimicrobial treatment with ceftriaxone: a case report Y Genchanok, SS Tolu, H Wang, S Arora The Permanente Journal 23, 2019 | 8 | 2019 |
| Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease SS Tolu, A Crouch, J Choi, Q Gao, M Reyes-Gil, UO Ogu, G Vinces, ... Annals of Hematology 101 (3), 541-548, 2022 | 7 | 2022 |
| Hemoglobin F mitigation of sickle cell complications decreases with aging SS Tolu, M Reyes‐Gil, UO Ogu, M Thomas, EE Bouhassira, CP Minniti American Journal of Hematology 95 (5), E122-E125, 2020 | 5 | 2020 |
| Efficacy and safety of direct oral factor xa inhibitors in 795 morbidly obese patients M Kushnir, Y Choi, R Eisenberg, D Rao, S Tolu, J Gao, W Mowrey, ... Blood 132, 423, 2018 | 4 | 2018 |
| High hemoglobin F in sickle cell disease: Waning protection with age SS Tolu, MR Gil, UO Ogu, J Choudhuri, R Fecher, G Sebastian, CP Minniti Blood 134, 3576, 2019 | 2 | 2019 |
| Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL SS Tolu, C Gribbin, MR Seshadri, Z Chen, E Orlando, J Grenet, R Toor, ... Blood 142, 1698, 2023 | 1 | 2023 |
| Acute and chronic pain management in patients with sickle cell disease in the modern era: a comprehensive review SS Tolu, L Van Doren Transfusion and Apheresis Science 61 (5), 103533, 2022 | 1 | 2022 |
| First Report of Compound Heterozygosity for Hb S (HBB: c.20A>T) and Hb Haringey (HBB: c.131A>G) UO Ogu, M Reyes Gil, SS Tolu, SA Acharya, CP Minniti Hemoglobin 45 (2), 136-139, 2021 | 1 | 2021 |
| Racial ethnic disparities in clinical/pathological features, treatment, and survival among patients with early-onset colorectal cancer. M Lyudmer, RJ Patel, A Chergui, SS Tolu, D Rao, A Kaubisch, JW Chuy, ... Journal of Clinical Oncology 39 (3_suppl), 21-21, 2021 | 1 | 2021 |
| Long-term hydroxyurea use is associated with lower levels of hematopoietic stem and progenitor cells in patients with sickle cell disease SS Tolu, K Wang, Z Yan, A Crouch, G Sebastian, M Chaitowitz, E Fornari, ... Blood 134, 985, 2019 | 1 | 2019 |
| Presence of isocitrate dehydrogenase (IDH) mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia (AML) EA Griffiths, B Carter-Cooper, S Tolu, LA Ford, RG Lapidus, M Wetzler, ... Blood 124 (21), 3724, 2014 | 1 | 2014 |
| Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma YK Ryu Tiger, S Jain, SK Barta, S Tolu, B Estrella, A Sawas, JK Lue, ... Leukemia & Lymphoma, 1-10, 2024 | | 2024 |
